WO2006079719A3 - Nouveaux derives d'oximes heterocycliques, leur procede de preparation, les compositions pharmaceutiques qui les contiennent et leur utilisation pour le traitement de l’obesite - Google Patents

Nouveaux derives d'oximes heterocycliques, leur procede de preparation, les compositions pharmaceutiques qui les contiennent et leur utilisation pour le traitement de l’obesite Download PDF

Info

Publication number
WO2006079719A3
WO2006079719A3 PCT/FR2006/000174 FR2006000174W WO2006079719A3 WO 2006079719 A3 WO2006079719 A3 WO 2006079719A3 FR 2006000174 W FR2006000174 W FR 2006000174W WO 2006079719 A3 WO2006079719 A3 WO 2006079719A3
Authority
WO
WIPO (PCT)
Prior art keywords
same
pharmaceutical compositions
compositions containing
novel heterocyclic
oxime derivatives
Prior art date
Application number
PCT/FR2006/000174
Other languages
English (en)
Other versions
WO2006079719A2 (fr
Inventor
Cecile Parmenon
Marie-Claude Viaud-Massuard
Jerome Guillard
Catherine Dacquet
Alain Ktorza
Daniel-Henri Caignard
Original Assignee
Servier Lab
Cecile Parmenon
Marie-Claude Viaud-Massuard
Jerome Guillard
Catherine Dacquet
Alain Ktorza
Daniel-Henri Caignard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Cecile Parmenon, Marie-Claude Viaud-Massuard, Jerome Guillard, Catherine Dacquet, Alain Ktorza, Daniel-Henri Caignard filed Critical Servier Lab
Priority to CA002596156A priority Critical patent/CA2596156A1/fr
Priority to MX2007008995A priority patent/MX2007008995A/es
Priority to EA200701477A priority patent/EA200701477A1/ru
Priority to US11/883,107 priority patent/US20090124656A1/en
Priority to EP06709171A priority patent/EP1844015A2/fr
Priority to JP2007552679A priority patent/JP2008528560A/ja
Priority to AU2006208812A priority patent/AU2006208812A1/en
Priority to BRPI0607087-6A priority patent/BRPI0607087A2/pt
Publication of WO2006079719A2 publication Critical patent/WO2006079719A2/fr
Publication of WO2006079719A3 publication Critical patent/WO2006079719A3/fr
Priority to NO20074347A priority patent/NO20074347L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Composés de formule (I): dans laquelle: > R1, R2, R3, R4 et X sont tels que définis dans la description, > A représente une chaîne alkylène telle que définie dans la description, > B représente un groupement alkyle ou alkényle substitués par un groupement (II) ou R7, ou B représente un groupement (III) ou R7. Médicaments
PCT/FR2006/000174 2005-01-27 2006-01-26 Nouveaux derives d'oximes heterocycliques, leur procede de preparation, les compositions pharmaceutiques qui les contiennent et leur utilisation pour le traitement de l’obesite WO2006079719A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA002596156A CA2596156A1 (fr) 2005-01-27 2006-01-26 Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MX2007008995A MX2007008995A (es) 2005-01-27 2006-01-26 Nuevos derivados de oximas heterociclicas, metodo para su preparacion, composiciones farmaceuticas que los contienen y su uso para el tratamiento de la obesidad.
EA200701477A EA200701477A1 (ru) 2005-01-27 2006-01-26 Новые гетероциклические соединения оксима, способ их получения и фармацевтические композиции, которые их содержат
US11/883,107 US20090124656A1 (en) 2005-01-27 2006-01-26 Heterocyclic Oxime Compounds a Process for Their Preparation and Pharmaceutical Compositions Containing Them
EP06709171A EP1844015A2 (fr) 2005-01-27 2006-01-26 Nouveaux derives d'oximes heterocycliques, leurs procede de preparation , les compositions pharmaceutiques qui les contiennent et leurs utilisation pour le traitement de l'obesite
JP2007552679A JP2008528560A (ja) 2005-01-27 2006-01-26 新規な複素環式オキシム誘導体、それらの製造方法及びそれらを含む医薬組成物
AU2006208812A AU2006208812A1 (en) 2005-01-27 2006-01-26 Novel heterocyclic oxime derivatives, method for preparing same and pharmaceutical compositions containing same
BRPI0607087-6A BRPI0607087A2 (pt) 2005-01-27 2006-01-26 derivados de oximas heterocìclicos, o respectivo processo de preparo e as composições farmacêuticas que os contêm
NO20074347A NO20074347L (no) 2005-01-27 2007-08-27 Nye heterocykliske oksimforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0500842A FR2881137B1 (fr) 2005-01-27 2005-01-27 Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR0500842 2005-01-27

Publications (2)

Publication Number Publication Date
WO2006079719A2 WO2006079719A2 (fr) 2006-08-03
WO2006079719A3 true WO2006079719A3 (fr) 2006-09-28

Family

ID=34954346

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2006/000174 WO2006079719A2 (fr) 2005-01-27 2006-01-26 Nouveaux derives d'oximes heterocycliques, leur procede de preparation, les compositions pharmaceutiques qui les contiennent et leur utilisation pour le traitement de l’obesite

Country Status (16)

Country Link
US (1) US20090124656A1 (fr)
EP (1) EP1844015A2 (fr)
JP (1) JP2008528560A (fr)
KR (1) KR20070103447A (fr)
CN (1) CN101133028A (fr)
AR (1) AR052891A1 (fr)
AU (1) AU2006208812A1 (fr)
BR (1) BRPI0607087A2 (fr)
CA (1) CA2596156A1 (fr)
EA (1) EA200701477A1 (fr)
FR (1) FR2881137B1 (fr)
MA (1) MA29257B1 (fr)
MX (1) MX2007008995A (fr)
NO (1) NO20074347L (fr)
WO (1) WO2006079719A2 (fr)
ZA (1) ZA200706249B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2909379B1 (fr) * 2006-11-30 2009-01-16 Servier Lab Nouveaux derives heterocycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
EP2315739B1 (fr) * 2008-08-25 2014-11-12 DuPont Electronic Polymers L.P. Nouveaux propanoates et leurs procédés de préparation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016298A1 (fr) * 1990-04-20 1991-10-31 Pfizer Inc Acides hydroxamiques et n-hydroxy-urees anti-inflammatoires
WO2001057002A1 (fr) * 2000-02-02 2001-08-09 Les Laboratoires Servier Derives d'azoles condenses et leur utilisation comme agents hypoglycemiants
FR2830012A1 (fr) * 2001-09-21 2003-03-28 Servier Lab Nouveaux derives heterocycliques, leur procede de preparation et les compositions pharamaceutiques qui les contiennent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602130A (en) * 1987-03-20 1997-02-11 Allergan Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
WO2004072041A1 (fr) * 2003-02-12 2004-08-26 Care X S.A. Tetrahydroquinoleines utilisees comme agonistes des recepteurs hepatiques
US7476673B2 (en) * 2003-12-30 2009-01-13 Allergan, Inc. Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016298A1 (fr) * 1990-04-20 1991-10-31 Pfizer Inc Acides hydroxamiques et n-hydroxy-urees anti-inflammatoires
WO2001057002A1 (fr) * 2000-02-02 2001-08-09 Les Laboratoires Servier Derives d'azoles condenses et leur utilisation comme agents hypoglycemiants
FR2830012A1 (fr) * 2001-09-21 2003-03-28 Servier Lab Nouveaux derives heterocycliques, leur procede de preparation et les compositions pharamaceutiques qui les contiennent

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JANUCZ J.M. AND CO: "New cyclooxygenase-2/5-lipoxygenase inhibitors.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 41, no. 7, 1998, pages 1124 - 1137, XP002389242 *
LOHRAY B B ET L: "Novel euglycemic and hypolidemic agents. 1", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 41, no. 10, 1998, pages 1619 - 1630, XP002149048, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
FR2881137A1 (fr) 2006-07-28
MX2007008995A (es) 2007-09-18
JP2008528560A (ja) 2008-07-31
BRPI0607087A2 (pt) 2009-08-04
US20090124656A1 (en) 2009-05-14
WO2006079719A2 (fr) 2006-08-03
AR052891A1 (es) 2007-04-11
MA29257B1 (fr) 2008-02-01
CN101133028A (zh) 2008-02-27
EP1844015A2 (fr) 2007-10-17
CA2596156A1 (fr) 2006-08-03
KR20070103447A (ko) 2007-10-23
FR2881137B1 (fr) 2007-03-02
NO20074347L (no) 2007-08-27
ZA200706249B (en) 2008-11-26
AU2006208812A1 (en) 2006-08-03
EA200701477A1 (ru) 2008-02-28

Similar Documents

Publication Publication Date Title
WO2008081096A3 (fr) Derives quinolinyliques, leur procede de preparation. les compositions pharmaceutiques qui les contiennent et leur utilisation comme agents hypoglycemiants et hypoli pemiants
EP1982982A4 (fr) Nouveau derive de coumarine ayant une activite antitumorale
NO20055688L (no) Organiske forbindelser
MY140528A (en) Spiroketal derivatives and their use as therapeutic agents for diabetes
WO2007103550A3 (fr) Derives d'aminothiazole substitues presentant une activite anti-hcv
WO2008114819A1 (fr) Nouveau composé d'adénine
WO2008114817A1 (fr) Nouveau composé d'adénine
TW200714598A (en) Urea derivatives, methods for their manufacture, and uses therefor
ES2368594T3 (es) Derivados sustituidos de ciclohexilmetilo.
TW200738667A (en) Preparation method for dioxan-2-ylalkylcarbamate derivatives and intermediate thereof
EP1775289A4 (fr) Nouveaux dérivés imidazolidine
WO2008006969A3 (fr) Nouveaux derives tetracycuques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ATE501103T1 (de) Organische verbindungen
IL183373A0 (en) 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
MX2009003927A (es) Derivado espirocetal de tioglucosa y uso del mismo como un agente terapeutico para la diabetes.
TW200616559A (en) Lipase inhibitory agent
JO2616B1 (ar) مركبات ثلاثية الحلقات جديدة، طريقة من أجل تحضيرها ومركباتها الصيدلانية
DE502006008710D1 (de) Substituierte tetrahydroisochinoline als mmp-inhibitoren, verfahren zu ihrer herstellung und ihre verwendung als medikament
TNSN07395A1 (en) Novel phenyl-pyridinyl-piperazine derivatives, a method for the production thereof and pharmaceutical compositions containing said derivatives
NO20074346L (no) Nye heterocykliske oksimforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
WO2007122792A3 (fr) Composition inhibitrice de formation de biofilm
WO2008049997A8 (fr) Derives indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TW200619201A (en) Process for the preparation of pyrazoles
EA200400867A3 (ru) Новые соединения гетероциклического оксима, способ их получения и фармацевтические композиции, содержащие их
WO2006079719A3 (fr) Nouveaux derives d'oximes heterocycliques, leur procede de preparation, les compositions pharmaceutiques qui les contiennent et leur utilisation pour le traitement de l’obesite

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006709171

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 556522

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 5623/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 11883107

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/008995

Country of ref document: MX

Ref document number: 2006208812

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2596156

Country of ref document: CA

Ref document number: 2007552679

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020077018500

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2006208812

Country of ref document: AU

Date of ref document: 20060126

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006208812

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 10240

Country of ref document: GE

WWE Wipo information: entry into national phase

Ref document number: 200701477

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 200680006477.4

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2006709171

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0607087

Country of ref document: BR

Kind code of ref document: A2